Moderna in prime position to offer first combined flu/Covid shot
Covid-19 stock market darling Moderna (MRNA) appears to be getting its mojo back with investors following a punishing 85% drop in the shares from their September 2021 highs.Over the last six months Moderna's shares have more than doubled and despite the fall over the past couple of years, they remain one of the best performers in the benchmark S&P 500, notching up gains of 880% over the last five